Elsevier

Pathologie Biologie

Volume 55, Issue 1, February 2007, Pages 37-48
Pathologie Biologie

Trisomy 8 as the sole chromosomal aberration in acute myeloid leukemia and myelodysplastic syndromes

https://doi.org/10.1016/j.patbio.2006.04.007Get rights and content

Abstract

Trisomy 8 as the sole abnormality is the most common karyotypic finding in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), occurring in approximately 5% and 10% of the cytogenetically abnormal cases, respectively. However, despite the high frequency of +8, much remains to be elucidated as regards its epidemiology, etiology, clinical impact, association with other chromosomal abnormalities, cell of origin, and functional and pathogenetic consequences. Here, we summarize and review these various aspects of trisomy 8, focusing on AMLs and MDS harboring this abnormality as a single change.

Introduction

Already in the late 1950s and early 1960s, cytogenetic studies of acute myeloid leukemias (AMLs) revealed that many of them were aneuploid, often with hyperdiploid modal numbers at 47 or 48 [1], [2], [3]. Although it was not possible to characterize further the chromosomal abnormality patterns in this pre-banding era, one aberration seemed quite common, namely a “group C-trisomy” [4], [5]. When the various chromosome banding techniques were introduced in the 1970s, it was soon realized that the extra C chromosome in AML, as well as in myelodysplastic syndromes (MDS), in the vast majority of the cases represented a trisomy 8 [6], [7], [8]. To date, close to 500 AMLs and 400 MDS with this abnormality as the sole chromosomal anomaly have been published [9].

In spite of the quite substantial number of trisomy 8-positive cases reported, many issues regarding the epidemiology, etiology, morphologic, immunophenotypic, and prognostic features, association with other genetic abnormalities, cell of origin, and the pathogenetic impact of +8 still needs to be clarified, as will be illustrated in the present review of AML and MDS with trisomy 8 as the sole chromosomal change.

Section snippets

Epidemiology

A survey of cytogenetically abnormal AML and MDS cases reported in the literature [9] shows that trisomy 8 is present in 16–17% of these disorders and that it is the sole change in 6 and 11% of the AMLs and MDS, respectively (Table 1, Table 2); frequencies agreeing well with published series of karyotypically characterized AMLs and MDS [10], [11], [12], [13], [14]. In fact, +8 is, on the whole, the most common chromosomal change in AML and the second, next to monosomy 7, in MDS; as the sole

Etiology

Apart from the fact that trisomy 8 most likely arises through non-disjunction, little is known about the constitutional/environmental risk factors for this chromosome abnormality.

It is generally accepted that +8 in AML and MDS is an acquired abnormality, being present in the neoplastic cells only. However, trisomy 8 may also be constitutional, occurring as a mosaicism (CT8M) in approximately 0.1% of all recognized pregnancies [32]. Typically, CT8M is the consequence of a postzygotic

Morphologic, immunophenotypic, and prognostic features

Although +8 as the sole change may be found in all morphologic subgroups of AML, it has been reported that it is particularly frequent in M1, M2, M4, and M5, with a higher incidence in M5a than in M5b [12], [13], [29], [58], [59], [60], [61], [62], [63]. An updated database search [9] reveals that the frequencies of +8 as the sole change vary significantly among the different morphologic subtypes, being most common in M5, albeit with identical incidences in the M5a and M5b subgroups (Table 1).

Trisomy 8 associated with other chromosomal abnormalities

In AML, trisomy 8 also occurs in association with other abnormalities in 10% of the cytogenetically abnormal cases (Table 1). In fact, trisomy 8 is quite common as a secondary change to a large number of primary AML-associated translocations and inversions [81], being particularly prevalent in cases with t(7;12), t(9;11), and t(1;11) (Table 7). Furthermore, it is the most common secondary change in AMLs with t(9;11)(p21;q23), t(9;22)(q34;q11), t(11;19)(q23;p13), and t(15;17)(q22;q21), and the

Cell of origin

During the past decade, cancer stem cells, the existence of which was first proposed more than 40 years ago, have received much attention [92], [93], [94]. It is now generally accepted, or at least widely believed, that hematologic malignancies are sustained by leukemic stem cells, capable of both initiating and maintaining the disease. Apart from functional studies, FISH analyses of neoplasia-associated genetic abnormalities in morphologically or phenotypically defined cell populations have

Pathogenetic impact of trisomy 8

Although several attempts to elucidate the pathogenetic impact of +8 have been made, the functional and molecular genetic outcome of this abnormality remains elusive. Possible mechanisms that may be involved include global gene expression changes, resulting from the gene dosage effect generated by the trisomy, deregulation of imprinted loci, and duplication of rearranged or mutated genes present in the extra chromosome 8. The pros and cons of these various possibilities are reviewed below.

Trisomy 8 is not sufficient for leukemogenesis

Trisomy 8 is an important early event, but several lines of evidence quite strongly indicate that it is not sufficient for leukemogenesis. First, although individuals with CT8M have an increased risk of myeloid malignancies, only a minority develop AML or MDS, with a latency of several years [37], [39], [42]. Second, several cytogenetic as well as clonality studies of trisomy 8-positive MDS cases have indicated that +8 is not the primary event in the malignant transformation, i.e. also the

Acknowledgments

The original research on which this article is based was supported by the Swedish Cancer Society and the Swedish Children's Cancer Foundation. We are grateful to Dr. Thoas Fioretos, Dr. Fredrik Mertens, Dr. Nils Mandahl, and Dr. Felix Mitelman for helpful comments and suggestions.

References (167)

  • C.A. Schiffer et al.

    Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia

    Blood

    (1989)
  • M. Zollino et al.

    Constitutional trisomy 8 and myelodysplasia: report of a case and review of the literature

    Leuk. Res.

    (1995)
  • D. Satge et al.

    Aspects of the neoplasms observed in patients with constitutional autosomal trisomy

    Cancer Genet. Cytogenet.

    (1996)
  • J. Welborn

    Constitutional chromosome aberrations as pathogenetic events in hematologic malignancies

    Cancer Genet. Cytogenet.

    (2004)
  • O.A. Haas et al.

    Hypothesis: meiotic origin of trisomic neoplasms

    Cancer Genet. Cytogenet.

    (1993)
  • L.M. Secker-Walker et al.

    Constitutional and acquired trisomy 8

    Leuk. Res.

    (1995)
  • T. Ariyama et al.

    Clonal origin of Philadelphia chromosome negative cells with trisomy 8 appearing during the course of alpha-interferon therapy for Ph positive chronic myelocytic leukemia

    Cancer Genet. Cytogenet.

    (1995)
  • F. Mitelman et al.

    Chromosome pattern, occupation, and clinical features in patients with acute non-lymphocytic leukemia

    Cancer Genet. Cytogenet.

    (1981)
  • W.S. Stillman et al.

    The benzene metabolite, hydroquinone, selectively induces 5q31- and -7 in human CD34+CD19- bone marrow cells

    Exp. Hematol.

    (2000)
  • L. Zhang et al.

    Use of OctoChrome fluorescence in situ hybridization to detect specific aneuploidy among all 24 chromosomes in benzene-exposed workers

    Chem. Biol. Interact.

    (2005)
  • J. Björk et al.

    Smoking and acute myeloid leukemia: associations with morphology and karyotypic patterns and evaluation of dose–response relations

    Leuk. Res.

    (2001)
  • R. Berger et al.

    Cytogenetic studies on 519 consecutive de novo acute nonlymphocytic leukemias

    Cancer Genet. Cytogenet.

    (1987)
  • J. Musilova et al.

    Chromosome study of 85 patients with myelodysplastic syndrome

    Cancer Genet. Cytogenet.

    (1988)
  • G. Perea et al.

    Adverse prognostic impact of CD36 and CD2 expression in adult de novo acute myeloid leukemia patients

    Leuk. Res.

    (2005)
  • R. Berger et al.

    Prognostic significance of chromosomal abnormalities in acute nonlymphocytic leukemia: a study of 343 patients

    Cancer Genet. Cytogenet.

    (1987)
  • D. Grimwade et al.

    The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial

    Blood

    (1998)
  • S.C. Raimondi et al.

    Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study—POG 8821

    Blood

    (1999)
  • D. Grimwade et al.

    The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial

    Blood

    (2001)
  • J.C. Byrd et al.

    Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

    Blood

    (2002)
  • P.C. Nowell et al.

    Prognostic significance of single chromosome abnormalities in preleukemic states

    Cancer Genet. Cytogenet.

    (1989)
  • F. Solé et al.

    Cytogenetic studies in 112 cases of untreated myelodysplastic syndromes

    Cancer Genet. Cytogenet.

    (1992)
  • V. Beyer et al.

    Polysomy 8 defines a clinico-cytogenetic entity representing a subset of myeloid hematologic malignancies associated with a poor prognosis: report on a cohort of 12 patients and review of 105 published cases

    Cancer Genet. Cytogenet.

    (2005)
  • S. Nguyen et al.

    A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup

    Blood

    (2002)
  • J. Delaunay et al.

    Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup

    Blood

    (2003)
  • J. Yan et al.

    Trisomy 8 and monosomy 7 detected in bone marrow using primed in situ labeling, fluorescence in situ hybridization, and conventional cytogenetic analyses. A study of 54 cases with hematological disorders

    Cancer Genet. Cytogenet.

    (2001)
  • R.E. Kibbelaar et al.

    Detection of monosomy 7 and trisomy 8 in myeloid neoplasia: a comparison of banding and fluorescence in situ hybridization

    Blood

    (1993)
  • J.C.Y. Wang et al.

    Cancer stem cells: lessons from leukemia

    Trends Cell Biol.

    (2005)
  • R.E. Kibbelaar et al.

    Combined immunophenotyping and DNA in situ hybridization to study lineage involvement in patients with myelodysplastic syndromes

    Blood

    (1992)
  • J. Anastasi et al.

    Cytogenetic clonality in myelodysplastic syndromes studied with fluorescence in situ hybridization: lineage, response to growth factor therapy, and clone expansion

    Blood

    (1993)
  • K. van Lom et al.

    In situ hybridization on May-Grünwald Giemsa-stained bone marrow and blood smears of patients with hematologic disorders allows detection of cell-lineage-specific cytogenetic abnormalities

    Blood

    (1993)
  • D. Haase et al.

    Evidence for malignant transformation in acute myeloid leukemia at the level of early hematopoietic stem cells by cytogenetic analysis of CD34+ subpopulations

    Blood

    (1995)
  • B. Mehrotra et al.

    Cytogenetically aberrant cells in the stem cell compartment (CD34+lin) in acute myeloid leukemia

    Blood

    (1995)
  • K. Saitoh et al.

    Fluorescence in situ hybridization of progenitor cells obtained by fluorescence-activated cell sorting for the detection of cells affected by chromosome abnormality trisomy 8 in patients with myelodysplastic syndromes

    Blood

    (1998)
  • A.A. Sandberg et al.

    The chromosome constitution of human marrow in various developmental and blood disorders

    Am. J. Hum. Genet.

    (1960)
  • A.G. Baikie et al.

    Cytogenetic studies in acute leukaemia

    BMJ

    (1961)
  • D.A. Hungerford et al.

    Chromosome studies in human leukemia. III. Acute granulocytic leukemia

    J. Natl. Cancer Inst.

    (1962)
  • A.A. Sandberg et al.

    Chromosomal differences among the acute leukemias

    Ann. N. Y. Acad. Sci.

    (1964)
  • K. Hellström et al.

    An extra C chromosome and various metabolic abnormalities in the bone marrow from a patient with refractory sideroblastic anaemia

    Scand. J. Haematol.

    (1971)
  • A. de la Chapelle et al.

    8-Trisomy in the bone marrow. Report of two cases

    Clin. Genet.

    (1972)
  • Mitelman F, Johansson B, Mertens F. Mitelman Database of Chromosome Aberrations in Cancer....
  • Cited by (84)

    • Generation of a novel isogenic trisomy panel in human embryonic stem cells via microcell-mediated chromosome transfer

      2019, Biochemical and Biophysical Research Communications
      Citation Excerpt :

      Thus, genome editing technologies applied to Ts8-ES cells may be able to confirm critical genetic aberration of Ts8-associated leukaemogenesis. In addition, Ts8 is common together with other chromosomal abnormalities in many types of neoplastic disorders [10]. Therefore, the Ts8-ES cell line is useful to uncover the mechanism of tumourigenesis associated with multiple chromosomal aberrations by transfer of an additional chromosome to the Ts8-ES cell line via MMCT.

    View all citing articles on Scopus
    View full text